D009190DisordersC15.378.190.625543450.762111Myelodysplastic Syndromesprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson6.427590.02598654research area of0.9948890.0173506262subject area forMedicine-Hematology and OncologyPathologyUniversity of ChicagoLucyGodley22VmD60QeczMknJtY0fp/Cv/+94=Lucy Godley41.78927490000000-87.601250000000001017Godley, LucyProfessorRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.ProfessorJamesVardimanJames W. Vardiman41.78927490000000-87.601250000000001630Vardiman, JamesEmeritus/EmeritaOlatoyosiOdenikew21tDq8cEun5hHlsaUXv9Gq0+s+oOlatoyosi Odenike41.78927490000000-87.60125000000000399Odenike, OlatoyosiProfessor38036712Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AMAnnals of hematologyA multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024 Jan; 103(1):105-116.Ann Hematol2023-12-01T00:00:002023A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.38096805Nawas MT, Kosuri SBlood advancesUtility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML. Blood Adv. 2024 02 13; 8(3):553-561.Blood Adv2024-02-13T00:00:002024Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.38135371Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MRThe Lancet. HaematologyOral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.Lancet Haematol2024-01-01T00:00:002024Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.38426560Cobaleda C, Godley LA, Nichols KE, Wlodarski MW, Sanchez-Garcia ICancer discoveryInsights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions. Cancer Discov. 2024 Mar 01; 14(3):396-405.Cancer Discov2024-03-01T00:00:002024Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions.38490765Trottier AM, Feurstein S, Godley LABest practice & research. Clinical haematologyGermline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders. Best Pract Res Clin Haematol. 2024 Mar; 37(1):101537.Best Pract Res Clin Haematol2024-02-01T00:00:002024Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Emeritus/EmeritaEmeritus/Emeritatrue1ProfessorProfessorDanielArberDaniel Arber0.000000000000000.000000000000003406Arber, DanielProfessor